Drugs News and Research

RSS

Newer GLP-1 medications may reduce alcohol-related hospitalization risk

Use of newer GLP-1 receptor agonists (semaglutide or tirzepatide) for obesity or diabetes by people with alcohol-use disorder was associated with a reduction in alcohol-related admissions to hospital, finds a study published online in the open access journal BMJ Open.

21 Jul 2026

AI-powered PeptiVerse could accelerate peptide drug discovery

Penn Engineers have developed PeptiVerse, an AI-powered platform that predicts key chemical and biological properties of peptides, the strings of amino acids whose medical potential has been demonstrated by the success of GLP-1 drugs, the widely used weight-loss treatments.

21 Jul 2026

Repeatedly losing and gaining weight may accelerate muscle loss

Repeatedly losing and gaining weight may do more than frustrate dieters - it also accelerates muscle loss in middle-aged people, according to new UC San Francisco research that comes as weight-loss medications transform obesity treatment.

21 Jul 2026

City of Hope launches trial to map how tumors change during immunotherapy resistance

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by U.S. News & World Report, has opened an innovative Phase 2 clinical trial designed to map how tumors change as they begin to resist immunotherapy, treatment that improves the immune system's ability to fight disease.

21 Jul 2026

New BRAF protein conformation opens avenues for cancer treatment

Several types of cancer are triggered by mutations in a protein called BRAF. Researchers at the Paul Scherrer Institute PSI have resolved a previously unknown conformation adopted by this protein during cell proliferation.

21 Jul 2026

Tailored gene therapy dramatically reduces childhood epilepsy seizures in trial

SCN2A‑related developmental epileptic encephalopathy (DEE) is a rare, severe form of childhood epilepsy and one of the most common causes of monogenic autism.

21 Jul 2026

Unlocking the untapped 90%: Membrane protein purification as a three hours routine workflow

Automated, detergent-free purification preserves native membrane protein structure while supporting more reliable target validation workflows.

From Analytik Jena 21 Jul 2026

New tumor organoids strengthen precision oncology research

Significant advances have been made in the development of patient-derived tumor "organoids" for preclinical research, in two new studies led by Weill Cornell Medicine investigators.

20 Jul 2026

Study links severe floods to higher opioid overdose deaths in rural Appalachia

Severe flooding may contribute to higher mortality rates from opioid use in rural Appalachia, according to a study by researchers at Penn State.

20 Jul 2026

High costs continue limiting insurance coverage for GLP-1 medications

Despite growing evidence that GLP-1 medications improve health and are worth their cost, many insurance plans still limit coverage. University of Mississippi researchers are examining why, and where that leaves patients.

20 Jul 2026

Dissolving microneedles could improve photodynamic skin cancer treatment

Photodynamic therapy (PDT) uses a light-sensitive drug and a specific wavelength of light to destroy cancer cells.

20 Jul 2026

New target makes cancer cells vulnerable to immune destruction

Researchers at the University of Illinois Chicago have identified a molecular switch that helps determine whether cancer cells remain soft and difficult to destroy or become stiff enough for the immune system to attack.

20 Jul 2026

Semaglutide vs. liraglutide: Head-to-head study reveals a diabetes risk difference

Researchers compared semaglutide with liraglutide in 57,456 insured adults without recorded diabetes or cardiovascular disease who initiated formulations indicated for chronic weight management. Semaglutide users had a lower risk of incident diabetes, particularly beyond six months of follow-up, but limited cardiovascular events prevented a precise comparison of cardiovascular risk.

20 Jul 2026

Semaglutide fuels rapid growth in US GLP-1RA use as payments rise

Nationally representative US data show GLP-1RA use rose 230% among adults with diabetes and 643% among those without reported diabetes between 2017 and 2022, largely driven by semaglutide. Mean annual out-of-pocket payments decreased, but mean total annual payments per user increased, raising concerns about long-term affordability.

20 Jul 2026

Rising antimicrobial resistance in children threatens life-saving antibiotic effectiveness

Antimicrobial resistance in children is rising globally and will worsen over the next decade, threatening the effectiveness of life‑saving antibiotics, according to a world-first monitoring platform.

20 Jul 2026

Prenatal use of certain medications can harm developing fetal brain

A review article by a University of Nebraska Medical Center/Child Health Research Institute research team underscores and describes how altering fundamental brain development processes can be detrimental for the developing baby.

20 Jul 2026

Daily polypill significantly improves cardiac function in heart failure patients

Treatment with a "polypill" that combines multiple medications into a single daily dose significantly enhanced cardiac function and reduced hospitalizations for patients with heart failure, according to a study led by Michigan Medicine and UT Southwestern Medical Center.

20 Jul 2026

Inflammatory messenger substance interferon-alpha can trigger Sjögren's syndrome

Findings from Bonn, Edinburgh and Newcastle could give a boost to pharmaceutical research.

20 Jul 2026

GLP-1 weight-loss drugs may also reduce binge eating

Research indicates GLP-1RAs may effectively reduce binge eating severity, offering a complementary approach to existing psychological therapies for obesity.

20 Jul 2026

Popular diabetes drugs do not alter the risk of developing a blinding eye condition

An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - a type of medication that mimics the GLP-1 hormone - to lower blood sugar and support weight loss. Some research has suggested that their use can reduce the risk of developing other diseases.

17 Jul 2026